Etanercept treatment enhances clinical and neuroelectrophysiological recovery in partial spinal cord injury
Purchase on Springer.com
$39.95 / €34.95 / £29.95 *
* Final gross prices may vary according to local VAT.
To investigate the effect of an anti-TNF-α agent (etanercept) on recovery processes in a partial spinal cord injury (SCI) model using clinical and electrophysiological tests.
Twenty-four New Zealand rabbits were divided into three groups: group 1 [SCI + 2 ml saline intramuscular (i.m.), n = 8], group 2 (SCI + 2.5 mg/kg etanercept, i.m., 2–4 h after SCI, n = 8) and group 3 (SCI + 2.5 mg/kg etanercept, i.m., 12–24 h after SCI, n = 8). Rabbits were evaluated before SCI, immediately after SCI, 1 week after, and 2 weeks after SCI, clinically by Tarlov scale and electrophysiologically by SEP.
Tarlov scores of groups 2 and 3 were significantly better than group 1, 2 weeks after SCI. SEP recovery was significantly better in groups 2 and 3 than group 1, 2 weeks after SCI.
These results show that blocking TNF-α mediated inflammation pathway by an anti-TNF-α agent enhances clinical and electrophysiological recovery processes in partial SCI model.
Supplementary Material (0)
About this Article
- Etanercept treatment enhances clinical and neuroelectrophysiological recovery in partial spinal cord injury
European Spine Journal
Volume 21, Issue 12 , pp 2588-2593
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Spinal cord injury
- Somatosensory evoked potentials
- Industry Sectors
- Author Affiliations